Search results
Results from the WOW.Com Content Network
Aribit (Aripiprazole) tablets. Aripiprazole, sold under the brand names Abilify and Aristada, among others, is an atypical antipsychotic [8] primarily used in the treatment of schizophrenia, bipolar disorder, and irritability associated with autism spectrum disorder; [8] other uses include as an add-on treatment for major depressive disorder and tic disorders. [8]
Drug withdrawal, drug withdrawal syndrome, or substance withdrawal syndrome [1] is the group of symptoms that occur upon the abrupt discontinuation or decrease in the intake of pharmaceutical or recreational drugs. In order for the symptoms of withdrawal to occur, one must have first developed a form of drug dependence.
Aripiprazole lauroxil, sold under the brand name Aristada, is a long-acting injectable atypical antipsychotic that was developed by Alkermes. [3] [4] [5] It is an N-acyloxymethyl prodrug of aripiprazole that is administered via intramuscular injection once every four to eight weeks for the treatment of schizophrenia.
Aripiprazole (Abilify) - Partial agonist at the D 2 receptor. Considered the prototypical third-generation antipsychotic. [169] Aripiprazole lauroxil (Abilify Maintena) – Long-acting version of aripiprazole for injection. Brexpiprazole (Rexulti) – Partial agonist of the D 2 receptor. Successor of aripiprazole.
Antidepressant discontinuation syndrome, also called antidepressant withdrawal syndrome, is a condition that can occur following the interruption, reduction, or discontinuation of antidepressant medication following its continuous use of at least a month. [5]
Brexpiprazole was developed by Otsuka and Lundbeck, and is considered to be a successor to aripiprazole (Abilify). [15] It was approved for medical use in the United States in July 2015. [ 16 ] [ 17 ] A generic version was approved in August 2022. [ 18 ]
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
Inadequate efficacy may be due to nonadherence to therapy, which can influence treatment decisions. For example, long acting injectable (LAI) antipsychotics are often indicated in the setting of medication nonadherence. [1] Drug intolerance: Adverse effects can contribute to drug intolerance, potentially necessitating antipsychotic switching ...